Last reviewed · How we verify
Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Rozlytrek | entrectinib | Roche | High affinity nerve growth factor receptor | 2019-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Roche · 1 drug in Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion:
- Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion treatment updates — RSS
- Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion treatment updates — Atom
- Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion treatment updates — JSON
Cite this brief
Drug Landscape (2026). Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/solid-neoplasm-with-neurotrophic-receptor-tyrosine-kinase-gene-fusion. Accessed 2026-06-11.
Related
- Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing